Safety communication
FDA safety communication: Wegovy injection-site reactions
Wegovy · Announced 2025-03-12 · Last reviewed May 2026
Reviewed by the glpzoom Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.
Content current as of May 2026; updated when guidance or availability changes.
Based on a pattern of MedWatch reports, the FDA issued an updated safety communication reminding prescribers and patients of best practices to minimize injection-site reactions with Wegovy. Reports included localized erythema, induration, and lipohypertrophy at injection sites. The communication did not change the Wegovy label but reinforced manufacturer guidance: rotate injection sites between abdomen, thigh, and upper arm; avoid same exact location consecutive weeks; use room-temperature pens (refrigerated pens increase injection-site reactions); and monitor for signs of localized infection requiring medical evaluation.
What's affected
- All Wegovy users — patient education update, not a product recall
What patients should do
- Rotate injection sites systematically — track via a calendar or GLP-1 dose-schedule tool
- Allow pen to reach room temperature (15-30 min from refrigerator) before injecting
- Inspect injection site for redness, swelling, or warmth before next injection
- Report persistent or worsening site reactions to prescriber